In The News:
ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trialmore >
Oncobiologics Secures Financing from Sabby Management, LLCmore >
Oncobiologics Appoints Lawrence A. Kenyon as Chief Financial Officermore >
Oncobiologics Secures $31 Million Financingmore >
Noted Immunology Expert Joins Oncobiologics as Chief Medical Officermore >
Oncobiologics opens commercial launch manufacturing facilitymore >
ONS-3010 (Humira®/adalimumab biosimilar) meets primary endpoints in first clinical studymore >
Oncobiologics announces completion of clinical dosing for bevacizumab (Avastin® biosimilar) candidatemore >
Oncobiologics launches Phase I Clinical Trial for ONS-3010 Biosimilar version of Humira®more >

What We Do

Oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the therapeutic areas of immunology and oncology. Our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company.

We have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony™ Platform. Oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars.

Oncobiologics is actively working on eight biosimilar candidates.  The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials...more >

Our Pipeline

view full size >

Company Highlights

  • ONS-3010 (Humira® Biosimilar) and ONS-1045 (Avastin® Biosimilar) entering Phase III Clinical study in 1H/2016. 
  • Eight complex biosimilars currently in active pipeline.
  • BioSymphony™: A unique approach to biosimilars development and commercialization, synthesizing development, manufacturing, regulatory and program management expertise with best-in-class global clinical development and commercial partners.
  • Rigorous engagement of orthogonal analytics to demonstrate high biosimilarity of complex mAbs.
  • An integrated development and manufacturing engine capable of generating two INDs per year.
  • Led by a team of leading scientists and engineers from the world’s top biopharmaceutical companies working in the agile, unencumbered environment of a start-up.
  • 50,000 sq. ft. facility in Cranbury, NJ and expanding

Join Oncobiologics

Oncobiologics is a dynamic, inspiring workplace where we seek best-in-class candidates to join our existing team of renowned specialists. To learn more about opportunities with our team, please visit our careers page... more >